Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702140 | 0.93 | KMT2A (0.37) | TACR1KCNQ1HCRTR1HTR7TIPARP | |
| SCHEMBL701104 | 0.89 | HTR7 (0.39) | TACR1HSD11B1HCRTR1NAMPTHTR7 | |
| SCHEMBL3441795 | 0.88 | KCNQ1 (0.34) | TACR1HSD11B1KCNQ1HCRTR1NAMPT | |
| SCHEMBL3441798 | 0.88 | KCNQ1 (0.34) | TACR1HSD11B1KCNQ1HCRTR1NAMPT | |
| SCHEMBL5129990 | 0.88 | MEN1 (0.45) | TACR1KCNQ1HCRTR1NAMPTTIPARP | |
| SCHEMBL701062 | 0.86 | TACR1 (0.34) | TACR1HSD11B1TIPARPCCR5EPHX2 | |
| SCHEMBL703139 | 0.83 | BDKRB1 (0.39) | NAMPT | |
| SCHEMBL10246334 | 0.83 | BDKRB1 (0.39) | NAMPT | |
| Hydrochloric Acid SCHEMBL704835 | 0.82 | BDKRB1 (0.38) | NAMPT | |
| SCHEMBL701483 | 0.81 | HTR7 (0.40) | TACR1KCNQ1HCRTR1HTR7CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | claimed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | TACR1 18/4885HSD11B1 1506/4885KCNQ1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.